Immunogenicity of adjuvanted-influenza vaccine and RSV vaccine in cancer survivors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011959

Enrollment

240

Registered

2026-05-11

Start date

2025-11-19

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients receiving the following anticancer therapies were enrolled after providing written informed consent for study participation and biospecimen collection. Prior to vaccination, a standard

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer patients aged 50 years or older 2. Patients receiving the following treatments — immune checkpoint inhibitors (ICI), cytotoxic chemotherapy, combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy, antibody-drug conjugates (ADC) or bispecific T-cell engagers (BiTEs) — as well as patients who underwent hematopoietic stem cell transplantation (HSCT), categorized into those 6 months to 2 years post-transplantation and those more than 2 years post-transplantation. 3. Patients who can understand and agreed with the informed consents.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of influenza or RSV infection in the past 30 days 2. Patients having contraindication for any vaccination (e.g. egg allergy) 3. Patients considered by an infectious diseases physician to have a contraindication to vaccination (e.g., acute severe infection).

Design outcomes

Primary

Measure	Time frame
Humoral and Cellular Immune Responses Following Vaccination with Adjuvanted Influenza and RSV Vaccines	—

Secondary

Measure	Time frame
Safety of Adjuvanted Influenza and RSV Vaccination in Cancer Patients	—

Countries

Korea, Republic of

Contacts

Public ContactJune Young Chun

National Cancer Center

june.y.chun@gmail.com+82-31-920-0895

Outcome results